

40. (Amended) A fusion molecule comprising:

a) a DNA binding domain; and

a3 b) an enzymatic component of a chromatin remodeling complex or a functional fragment thereof, wherein the enzymatic component of a chromatin remodeling complex or functional fragment thereof is selected from the group consisting of a histone methyl transferase, a histone demethylase, a histone kinase, a histone phosphatase, a histone ubiquitinating enzyme, a histone-ADP-ribosylase and a histone protease.

44. (Amended) A method for modulating expression of a gene, the method comprising the steps of:

a4 a) contacting cellular chromatin with the fusion molecule according to claim 40; and

b) further contacting the cellular chromatin with a second molecule that binds to a target site in the gene and modulates expression of the gene.

a5 65. (Amended) The method of claim 60 wherein the first fusion molecule binds to two or more of the plurality of genes.

a6 67. (Amended) The method of claim 60 wherein the second molecule binds to two or more of the plurality of genes.

a7 72. (Amended) A method for producing the fusion polypeptide of claim 34, the method comprising the step of expressing the polynucleotide of claim 41 in a suitable host cell.

73. (Amended) A method for binding an exogenous molecule to a binding site, wherein the binding site is located within a region of interest in cellular chromatin, wherein the method comprises:

(a) contacting cellular chromatin with a fusion molecule according to claim 40; and

(b) introducing the exogenous molecule into the cell;

whereby the exogenous molecule binds to the binding site.

Attached hereto are a **version showing changes made** and a copy of a **currently pending claim set**.